![David A. Kennard](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David A. Kennard
Corporate Officer/Principal presso Royal Pharmaceutical Society of Great Britain
Posizioni attive di David A. Kennard
Società | Posizione | Inizio | Fine |
---|---|---|---|
Royal Pharmaceutical Society of Great Britain
![]() Royal Pharmaceutical Society of Great Britain Miscellaneous Commercial ServicesCommercial Services The Royal Pharmaceutical Society of Great Britain provides expertise and support to its member pharmacists. The private company is based in Great Britain. Alex MacKinnon has been the CEO of the British company since 2010. | Corporate Officer/Principal | - | - |
Storia della carriera di David A. Kennard
Precedenti posizioni note di David A. Kennard
Società | Posizione | Inizio | Fine |
---|---|---|---|
SILENCE THERAPEUTICS PLC | Direttore operativo | - | - |
NeuroTargets Ltd.
![]() NeuroTargets Ltd. Pharmaceuticals: MajorHealth Technology NeuroTargets, Inc. develops novel therapeutic products. It discovers and develops new drugs for neurological diseases. The company develops products in the fields of diabetic neuropathy, pain resulting from nerve damage, spinal cord injuries and other trauma, and brain diseases associated with cognitive impairment such as stroke and Alzheimer's disease. NeuroTargets was founded in 1999 and is located at Guildford, UK. | Direttore/Membro del Consiglio | 01/08/2004 | - |
Presidente | 01/08/2004 | - | |
YM BioSciences, Inc.
![]() YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | 01/01/2004 | - |
Formazione di David A. Kennard
University of London | Doctorate Degree |
Statistiche
Distribuzione geografica
Regno Unito | 5 |
Canada | 2 |
Posizioni
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Masters Business Admin | 1 |
Settori
Commercial Services | 3 |
Health Technology | 3 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
SILENCE THERAPEUTICS PLC | Commercial Services |
Aziende private | 3 |
---|---|
YM BioSciences, Inc.
![]() YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Royal Pharmaceutical Society of Great Britain
![]() Royal Pharmaceutical Society of Great Britain Miscellaneous Commercial ServicesCommercial Services The Royal Pharmaceutical Society of Great Britain provides expertise and support to its member pharmacists. The private company is based in Great Britain. Alex MacKinnon has been the CEO of the British company since 2010. | Commercial Services |
NeuroTargets Ltd.
![]() NeuroTargets Ltd. Pharmaceuticals: MajorHealth Technology NeuroTargets, Inc. develops novel therapeutic products. It discovers and develops new drugs for neurological diseases. The company develops products in the fields of diabetic neuropathy, pain resulting from nerve damage, spinal cord injuries and other trauma, and brain diseases associated with cognitive impairment such as stroke and Alzheimer's disease. NeuroTargets was founded in 1999 and is located at Guildford, UK. | Health Technology |
- Borsa valori
- Insiders
- David A. Kennard
- Esperienza